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Abstract
Cisplatin induced apoptosis in regenerating liver after partial hepatectomy (PH). Apoptosis was determined by in situ end-
labeling and gel electrophoresis of DNA fragmentation. Characteristic DNA fragmentation was obvious at 4 h and peaked at
8 h after PH. The activity of Jun N-terminal kinase (JNK) transiently increased at 1 h after PH. However, in cisplatin-
injected rats, the JNK activity increased at 30 min and the increased level was maintained up to 4 h after PH. The in vivo
activation of JNK was confirmed by the increased level of the phosphorylated c-Jun protein. Western blot analysis showed
that the phosphorylated c-Jun level increased at 1 h and reached more than 30-fold the control level at 2 h after PH with
cisplatin. The c-jun mRNA levels also markedly increased at 1 h after PH with cisplatin. The protein level of p53 increased
after 1 h on cisplatin injection, but no significant change in the mRNA level was observed. The rise in the p53 protein level
was followed by the upregulation of p21WAF1=CIP1 mRNA and protein levels. These results suggested that the enhanced and
sustained JNK activation and the upregulation of p53 and p21WAF1=CIP1 were involved in hepatocyte apoptosis induced by
PH with cisplatin. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
The hepatocyte is a highly di¡erentiated cell that
rarely divides in the normal adult liver. However,
after two thirds partial hepatectomy (PH), most re-
maining hepatocytes promptly enter and progress in
the cell cycle in a synchronous manner [1]. The ¢rst
‘priming’ step, which makes quiescent hepatocytes
enter a state of replicative competence before they
can fully respond to growth factors, is an initiating
event in liver regeneration [2]. After the prereplica-
tive phase, the onset of DNA synthesis occurs at 12^
16 h posthepatectomy in hepatocytes with a peak
level at 24 h. Recent works have shown that tumor
necrosis factor (TNF)-K, signaling through TNF re-
ceptor (TNFR)-1, may prime the hepatocytes and
initiate liver regeneration [3,4]. TNF-K triggers the
activation of two transcription factors, NFUB and
c-Jun/AP1 [3,5]. These transcription factors regulate
the gene expression of proteins involved in liver re-
generation.
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c-Jun, a member of the activator protein (AP1)
family of transcription factors, is increased within
30^60 min after PH [6]. c-Jun is the end target for
the JNK intracellular signaling pathway that is re-
sponsive to cellular stress and to TNF-K. Induction
of JNK activity is one of the earliest events in the
regeneration of liver after PH [6]. Inhibition of c-Jun
results in impaired hepatogenesis [7]. c-Jun/AP-1 is
required for DNA synthesis [6,8]. However, c-Jun/
AP-1 has been recently identi¢ed as an inducer of
apoptosis [9^12]. Strong and prolonged activation
of JNK has been reported in response to a variety
of stresses including UV light, TNF-K and chemo-
preventive drugs, any of which can trigger apoptosis
[13^16]. TNF-K activates JNK and JNK activation is
postulated to be involved in TNF-K-induced apopto-
sis [9,16^18]. Although TNF-K is required for initia-
tion and proliferation of hepatocytes after PH, TNF-
K can cause apoptosis. Many tumor cells are sensi-
tive to TNF-K-induced apoptosis, but normal cells
are usually resistant. Some cells undergo apoptosis
only when they are treated with TNF-K in the pres-
ence of other agents or when they are damaged [19^
21].
The anticancer drug, cis-diamminedichloroplati-
num(II) (cisplatin), has been shown to cause JNK
stimulation in cells [15,22]. Internucleosomal DNA
cleavage and ultrastructural change characteristic of
apoptosis have been observed following exposure to
cisplatin in murine L1210 leukemia, in Chinese ham-
ster ovary cell lines [23,24] and in proliferating rat
hepatoma cells, but not in nonproliferating thymo-
cytes [25]. The cell lines defective in JNK activation
were resistant to the lethal e¡ects of the DNA-dam-
aging drug [15]. These results suggest that cisplatin
induces apoptosis through the JNK signaling path-
way in replicative competent cells. We investigated
whether the ‘priming’ step was required for apoptosis
in hepatocytes and whether cisplatin-induced apopto-
sis was accompanied by JNK activation in regener-
ating liver.
The tumor suppressor gene p53 is now widely rec-
ognized as a transducer of genome damage into
growth arrest and/or apoptosis by transcriptional ac-
tivation of the gene encoding the cyclin-dependent
kinase inhibitor p21WAF1=CIP1 [26,27]. p21 has been
postulated to participate in growth suppression and
apoptosis as well as cell cycle progression [28]. Tu-
mor cells that have lost functional p53 exhibit resis-
tance to induction of apoptosis by a range of geno-
toxic agents, including anticancer drugs and
radiation [29^31]. In addition, p53 was shown to be
a substrate of JNK [32^34]. In the present study, the
possible role of JNK activation in the expression of
p53 and p21 was also examined.
The results showed that cisplatin induced apopto-
sis only in the primed hepatocytes after PH and that
cisplatin-induced apoptosis was preceded by a pro-
longed JNK activation and upregulation of p53 and
p21.
2. Materials and methods
2.1. Materials
The reagents were purchased from the following
sources: [2,3-3H(N)] putrescine (80 Ci/mmol),
ARC; Cisplatin, Sigma; SAPK/JNK Assay kit,
New England Biolabs; DIG RNA labeling kit and
DIG luminescent detection kit, Boehringer Mann-
heim Biochemica; Oligo(dT)cellulose (type 3), Col-
laborative Research; Gene screen nylon membrane,
NEN Research Products; Immobilon PVDF transfer
membranes, Millipore; Antibodies to c-Jun, p-c-
Jun(Ser-63), p53 and p21, Santa Cruz Biotechnology.
All other reagents were of analytical grade.
2.2. Animals
Male Wistar rats weighing 180^200 g were used for
all experiments. The animals were kept in a temper-
ature-controlled room with a 12:12-h light/dark cycle
and given commercial laboratory chow (MF, Orien-
tal Yeast Co., Osaka, Japan) and water ad libitum.
Two-thirds partial hepatectomy (PH) was performed
by the procedure of Higgins and Anderson [35]. Cis-
platin (10 mg/rat body weight), suspended in saline
was injected intraperitoneally immediately after PH
to the partially hepatectomized or normal (without
PH) rats. Control rats were partially hepatectomized
and received the same quantity of vehicle alone. The
rats were killed under diethyl ether anesthesia and
their livers were excised at various times.
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2.3. In situ end-labeling of 3P-OH ends of
DNA fragments
Paraformaldehyde-¢xed para⁄n-embedded liver
sections, obtained from cisplatin-injected normal
(no PH with cisplatin) rats and the regenerating liver
of control (PH only) or cisplatin-injected (PH with
cisplatin) rats at 8 h after PH and injection, were
processed for in situ detection of DNA fragmenta-
tion by the terminal deoxynucleotidyl transferase
(TdT)-mediated nick-end-labeling technique (TU-
NEL) [36] using an In Situ Cell Death Detection
kit (Boehringer-Mannheim, Germany). Brie£y, de-
para⁄nized tissue sections were enzymatically la-
beled with £uorescein-nucleotide via terminal deoxy-
nucleotidyl transferase and subsequently exposed to
horseradish peroxidase conjugated anti-£uorescein
antibody. Staining was developed in diaminobenzi-
dine and sections were counterstained with Mayer’s
hematoxylin.
2.4. Isolation and gel electrophoresis of DNA
The liver was homogenized in lysis bu¡er contain-
ing 50 mM Tris^HCl (pH 7.5), 10 mM EDTA and
0.5% sodium dodecyl sulfate (SDS), and incubated
overnight with proteinase K (200 Wg/ml) at 50‡C.
After RNase digestion, DNA was extracted and elec-
trophoresed on 2% agarose gels as previously de-
scribed [37].
2.5. Determination of the enzyme activities
2.5.1. GOT activity
The activity of serum glutamate oxaloacetate
transaminase (GOT) was measured spectrophotomet-
rically utilizing diagnostic kits (Wako Pure Chemical
Co., Osaka, Japan) and expressed as IU at 25‡C.
2.5.2. TGase II activity
The excised liver was homogenized with 5 volumes
of 50 mM Tris^HCl bu¡er (pH 7.3) containing 0.25
M sucrose, 10 mM L-mercaptoethanol, 1 mM phen-
ylmethylsulfonyl £uoride and 1 mM EDTA. The
TGase II activity of the liver homogenate was mea-
sured by detecting the incorporation of [3H]-
putrescine into N,NP-dimethylcasein [38] and ex-
pressed as nmol/h per mg protein. Protein was mea-
sured by the method of Lowry et al. [39] with bovine
serum albumin as the standard.
2.5.3. JNK activity assay
The activity of JNK was measured using a SAPK/
JNK assay kit (New England Biolabs) according to
the protocol provided by the manufacturer. Brie£y,
50 mg of the liver tissue was homogenized in 1 ml of
ice-cold lysis bu¡er. After centrifugation at 14 000Ug
for 10 min, the supernatant was collected and used
for determinations of protein concentration and JNK
activity. Protein was measured by the BCA protein
assay (Pierce Chemical). The supernatant (250 Wg of
protein) was then incubated with GST-c-Jun (1^89)
coupled to GSH-Sepharose beads overnight at 4‡C.
The beads were washed and the solid-phase kinase
reaction was carried out at 30‡C for 30 min. Phos-
phorylation of GST-c-Jun on Ser-63 was analyzed
after immunoblotting with phospho-speci¢c c-Jun-
(Ser-63) antibody.
2.6. Western blotting analysis
Nuclear proteins were prepared from the normal
and regenerating liver at each time point as previ-
ously described [40]. The protein concentration of
the resultant nuclear sample was determined by
BCA protein assay. For immunoblotting analysis,
equal amounts of nuclear proteins were electropho-
resed on SDS^polyacrylamide gels and transferred
on membranes. The membranes were blocked in
TBS with 0.05% Tween 20 and 10% nonfat dry
milk overnight, and incubated with a speci¢c anti-
body to p-c-Jun(Ser-63), c-Jun, p53 or p21. After
incubation with secondary antibody conjugated to
horseradish peroxidase, immunoreactive proteins
were detected by the enhanced chemiluminescence
system (ECL; Amersham). The chemiluminescent
signals were quantitated by a densitometer as de-
scribed previously [37]. Equal loading of protein
samples was con¢rmed by BCA protein assay and
staining of the gel with Coomassie Brilliant blue.
2.7. Isolation and Northern blotting analysis of RNA
Total RNA was extracted from the liver in 4 M
guanidium isothiocyanate [41] and fractionated by
a⁄nity chromatography on an oligo(dT)-cellulose
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column to obtain poly(A)-rich RNA. The concentra-
tions of RNA samples were measured by absorbance
at 260 nm. The purities of RNA samples were deter-
mined by the ratio of A260 nm/A280 nm (s 1.8) and by
electrophoresis in formaldehyde^agarose gels stained
with ethidium bromide. The RNA preparations were
denatured and electrophoresed on 1.2% agarose/2.2
M formaldehyde gels. After separation, the RNA
was transferred to Gene screen membranes by capil-
lary blotting. Hybridization was carried out using
Dig-labeled RNA probes and the chemiluminescent
signals were quantitated by a densitometer as de-
scribed previously [37]. Equal loading and the trans-
fer e⁄ciency of RNA samples were veri¢ed by the
intensity of ethidium bromide £uorescence of the
rRNA on the gel and the ¢lter. The levels of albumin
mRNA, which do not vary during 24 h after PH [42],
were con¢rmed to be comparable in the RNA sam-
ples used for blotting.
2.8. Preparation of RNA probe
The EcoRI/PstI fragment (1.8 kb) of c-jun (ATCC
63026), the EcoRI fragment (0.85 kb) of mouse p21
cDNA clone, p21-9C, the HindIII/AccI fragment (1.3
kb) of mouse p53 cDNA (RDB 1284), or the PstI
fragment (0.5 kb) of rat albumin cDNA was sub-
cloned into plasmid Bluescript. After linearization
of the plasmid, T7 RNA-polymerase was employed
to obtain run-o¡ transcripts of the antisense strands.
Transcription and labeling were performed utilizing
the commercial DIG RNA labeling system according
to the manufacturer’s instructions.
3. Results
3.1. Apoptosis induced by cisplatin
A characteristic ladder pattern of DNA was ob-
served in the cisplatin-injected rat liver on agarose
gel electrophoresis (Fig. 1). DNA isolated from the
control rat liver yielded bands only in the high mo-
lecular mass region. A time course study of DNA
fragmentation showed that signi¢cant DNA cleavage
was detectable as early as 2 h, obvious at 4 h and
peaked at 8h after PH in the cisplatin-injected rat
liver. Fig. 2 shows a representative example of in
situ labeling of apoptotic cells in liver sections from
the control and cisplatin-injected rats at 8 h after
PH. TUNEL-positive staining was observed in nuclei
and nuclear fragments with the morphological char-
acteristics of apoptosis in the cisplatin-injected liver
(PH with cisplatin), with negligible background
staining in the control (PH only) and also in the
cisplatin-injected normal (no PH with cisplatin) liver.
Apoptotic hepatocytes were rarely observed in the
cisplatin-injected normal liver, suggesting that the
priming step was required for cisplatin-induced apo-
ptosis of hepatocytes in vivo. The identi¢cation of
stained apoptotic bodies was con¢rmed by speci¢c
morphological criteria including nuclear condensa-
tion, cytoplasmic compaction and detachment from
neighboring cells [43]. In the present evaluation, he-
patocytes with necrotic morphology were rare and
foci of in£ammatory cells were absent under light
microscopy after hematoxylin and eosin staining.
3.2. E¡ects of cisplatin on the activities of serum GOT
and liver TGase II
As a functional assay substantiating that the e¡ect
of cisplatin is apoptotic and not necrotic, GOT re-
lease was determined as a marker of membrane in-
tegrity. The administration of cisplatin had no sig-
Fig. 1. Analysis of DNA fragmentation by agarose gel electro-
phoresis. Cisplatin (10 mg/kg body weight) was intraperitoneally
injected immediately after PH. Genomic DNA was isolated
from liver of control and cisplatin-injected rats at 2, 4, 8, 12,
and 24 h after PH. Lane M contained HindIII-digested VDNA
as a molecular size marker. The result presented here is typical
of four separate experiments.
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ni¢cant e¡ect on serum GOT activity during liver
regeneration as shown in Table 1, indicating that
necrosis was not caused by cisplatin up to 24 h after
PH at the dose level employed.
A rise in TGase II activity has been described as a
prominent feature of some cells undergoing chemi-
cally induced apoptotic cell death [44]. The TGase II
activity in cisplatin-injected rat liver was similar
to the control values during liver regeneration
(Table 1), indicating that the cisplatin-induced
apoptosis was not accompanied by an increase in
TGase II activity.
3.3. E¡ects of cisplatin on JNK activity and
phosphorylated c-Jun protein levels
JNK activity was induced to a detectable level at
15 min, peaked at 1 h and then decreased after 2 h
following PH (Fig. 3A,D). Cisplatin markedly in-
creased the JNK activity up to almost the maximal
level of the control at 30 min after PH. The JNK
activation with a peak at 2 h continued until 4 h after
PH in cisplatin-injected rats.
To determine the JNK activation in vivo, the levels
of phosphorylated c-Jun protein in the liver nuclear
fraction were measured by western blotting analysis.
As shown in Fig. 3B, the anti-p-c-Jun(Ser-63) anti-
body detected two bands with an apparent molecular
size of about 43 kDa and 45 kDa. This result was
consistent with reports that phospho-c-Jun was rec-
ognized as two bands [9,45]. In cisplatin-injected rats,
the more highly phosphorylated form (pp-c-Jun) ap-
peared at 1 h and increased at 2 h to a maximum,
which was more than 30-fold the phosphorylated c-
Jun (p-c-Jun) level of the control. The more highly
phosphorylated form with a slower migration (pp-c-
Jun) was not detected, but a faint band of the phos-
phorylated c-Jun (p-c-Jun) was observed at 1 h after
PH in the control (Fig. 3B,D).
Table 1
The e¡ect of cisplatin on the activities of serum GOT and liver TGase II after partial hepatectomy (PH)
Time after PH (h) GOT (IU) TGase II (nmol/h per mg protein)
Control Cisplatin Control Cisplatin
2 67.0 þ 3.2 56.8 þ 5.1 5.06 þ 0.45 4.67 þ 0.68
4 119.4 þ 10.1 84.8 þ 11.0 4.86 þ 0.38 4.96 þ 0.48
8 138.0 þ 10.2 154.5 þ 13.6 5.02 þ 0.51 4.25 þ 0.55
12 146.3 þ 8.0 135.2 þ 14.8 4.75 þ 0.65 4.17 þ 0.43
24 112.3 þ 15.0 151.5 þ 16.0 5.04 þ 0.79 3.94 þ 0.42
Normal 18.1 þ 1.6 4.86 þ 0.75
Cisplatin (10 mg/kg body weight) was intraperitoneally injected immediately after PH. At 2, 4, 8, 12, and 24 h after PH, the activities
of serum GOT and liver TGase II were determined as described in Section 2. Values are mean þ S.D. of 3^5 rats.
Fig. 2. In situ end-labeling of the apoptotic bodies in a liver
section of cisplatin-injected (upper) and control rat (lower) at
8 h after PH. Cisplatin (10 mg/kg body weight) was intraperito-
neally injected immediately after PH. Paraformaldehyde-¢xed
para⁄n-embedded liver sections, obtained from the regenerating
liver of cisplatin-injected and control rats at 8 h after PH, were
processed for in situ detection of DNA fragmentation by TU-
NEL as described in Section 2. TUNEL-stained nuclei are
marked by arrows. Hematoxylin counterstaining. The results
presented here are typical of four separate experiments (original
magni¢cation U400).
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3.4. E¡ects of cisplatin on c-Jun, p53 and p21 protein
expression
As shown in Fig. 3C, c-Jun was recognized as a
triplet, indicating that the two bands with slower
Fig. 3. E¡ects of cisplatin on JNK activation and the protein
levels of phosphorylated c-Jun, c-Jun, p53 and p21 during liver
regeneration. (A) JNK activity. Solid-phase in vitro JNK assays
were performed using the liver lysate and SAPK/JNK assay kit
as described in Section 2. The liver lysates were prepared from
the normal liver and the regenerating liver of the control and
cisplatin-injected rat liver at 0.25, 0.5, 1, 2 and 4 h after PH.
(B,C) Western blot analysis of phosphorylated c-Jun, c-Jun, p53
and p21 protein. The nuclear protein (6, 6, 60, and 40 Wg for
p-c-Jun, c-Jun, p53 and p21, respectively) of the normal liver
and the regenerating liver of control and cisplatin-injected rat
at 0.5, 1, 2 and 4 h after PH was resolved by SDS^PAGE
(10%, 8%, and 12.5% SDS^PAGE for c-Jun, p53 and p21, re-
spectively). After transfer, the blot was probed with antibody
and detected by ECL as described in Section 2. p-c-Jun, phos-
phorylated c-Jun; pp-c-Jun, more highly phosphorylated c-Jun.
The results presented are typical of six separate experiments.
(D) The results were quanti¢ed by densitometry and are graphi-
cally represented. Values represent mean þ S.E. (left rods, con-
trol; right rods, cisplatin-injected). The asterisks indicate statis-
tically signi¢cant di¡erences from the corresponding control
(P6 0.05).
Fig. 3 (continued).
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migrations correspond to the phosphorylated forms
of c-Jun (p-c-Jun and pp-c-Jun) as shown in Fig. 3B.
The major band of c-Jun protein and a faint band of
p-c-Jun increased to a detectable level at 30 min and
peaked at 1^2 h after PH in the control (Fig. 3C). In
the cisplatin-treated rats, two bands of phosphorylat-
ed forms as well as c-Jun protein were detected after
1 h to 4 h. The total c-Jun levels of the cisplatin-
injected rats increased to about 3-fold the corre-
sponding control at 2 and 4 h after PH. At 1 h after
PH, the total c-Jun levels in the cisplatin-injected rats
were similar to the corresponding control, but about
80% of c-Jun protein was of phosphorylated form
(pp-c-Jun and p-c-Jun) (Fig. 3C,D). The levels of
phosphorylated c-Jun further increased but the un-
phosphorylated c-Jun level was similar to the control
at 2 h after PH with cisplatin.
The protein levels of p53 did not signi¢cantly
change during 4 h after PH in the control (Fig.
3C). The injection of cisplatin increased the p53
amount from 1 h to 4 h after PH.
The p21 protein band was undetectable during 4 h
after PH in the control as shown in Fig. 3C. In the
cisplatin-injected rats, the protein band appeared at
2 h and increased at 4 h after PH.
3.5. E¡ects of cisplatin on gene expression during
liver regeneration
The e¡ects of cisplatin on the mRNA levels of c-
jun, p53 and p21WAF1=CIP1 were investigated as
shown in Fig. 4. The level of c-jun transcripts was
markedly increased at 1 and 2 h after PH by cisplatin
C
Fig. 4. E¡ects of cisplatin on the expression of c-jun, p53 and
p21 during liver regeneration after PH. (A) Poly(A)-rich RNA
(5 Wg) from normal (N) and regenerating liver of control or cis-
platin-injected rats at 0.25, 0.5, 1 and 2 h after PH was ana-
lyzed by Northern blotting using Dig-labeled RNA probes as
described in Section 2. The levels of albumin mRNA in the
RNA samples used for the blotting are shown to be compara-
ble by the blot hybridized with albumin probe. The results pre-
sented here are typical of six separate experiments. (B) The
mRNA levels were determined by densitometry and are graphi-
cally represented. Values represent mean þ S.E. (left rods, con-
trol ; right rods, cisplatin-injected). The asterisks indicate statis-
tically signi¢cant di¡erences from the corresponding control
(P6 0.05).
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injection. Scanning densitometry showed that the c-
jun mRNA level in cisplatin-injected liver increased
to about 13- and 7-fold the corresponding control
level at 1 and 2 h after PH, respectively (Fig. 4A,B).
The p53 mRNA levels were not signi¢cantly
changed during 2 h after PH in either the control
or cisplatin-injected rats. This result indicated that
the increase in p53 protein levels of the cisplatin-in-
jected rats was likely brought about by a posttran-
scriptional mechanism.
The p21 mRNA was barely detectable in the nor-
mal liver but increased to a detectable level at 30 min
peaking at 2 h after PH. The mRNA level of p21 in
cisplatin-injected liver increased to about 8-fold the
corresponding control level at 1 h after PH.
4. Discussion
This study clearly demonstrated that cisplatin in-
duced apoptosis at an early phase in regenerating
liver. Apoptosis was scarcely observed in the normal
quiescent hepatocytes after cisplatin injection. This
was consistent with the result that internucleosomal
DNA cleavage was not observed in nonproliferating
thymocytes but occurred in proliferating rat hepato-
ma cells following exposure to cisplatin [25]. The
priming step seems to be required for cisplatin-in-
duced apoptosis. TNF-K primes hepatocytes in liver
regeneration after PH [3]. Although TNF-K by itself
is not generally apoptotic, it can cause apoptosis
when given in conjunction with drugs that block
transcription and translation [19^21,46]. These ¢nd-
ings suggest a possible role for TNF-K signaling in
the apoptosis of regenerating liver after PH with cis-
platin.
Cisplatin-induced DNA fragmentation was pre-
ceded by a marked and prolonged increase in JNK
activity. The induction of JNK activity is an early
event after PH (Fig. 3A). However, this activation
was transient. The injection of cisplatin markedly
increased JNK activity after 30 min and the activa-
tion continued for up to 4 h following PH. The JNK
pathway was required in radiation-induced apoptosis
in T cells and JNK activation in T-cell apoptosis was
characterized by a persistent kinetics in contrast to
the transient induction in T-cell activation [10]. A
sustained JNK activation was also associated with
the initiation of apoptosis in rat mesangial cells [9].
These results suggest that the timing and duration of
the JNK activation is critical in determining whether
the cell will undergo apoptosis or progress through
the cell cycle in regenerating liver. The prolonged
JNK activation may switch the e¡ect of TNF-K
from proliferative to apoptotic.
The JNK activation in vivo was con¢rmed by the
increase in the phosphorylated c-Jun protein level in
the cisplatin-injected liver (Fig. 3B). Phosphorylation
of c-Jun by JNK is known to increase its transcrip-
tional activity. The c-jun gene is regulated by auto-
stimulation of its AP-1 or c-Jun-ATF2 heterodimer
binding site by c-Jun protein [47,48]. The levels of
c-jun mRNA also increased at 1 h in cisplatin-in-
jected rat liver after PH. The increase in the
mRNA levels was followed by an increase in c-Jun
protein. These results suggest that cisplatin-evoked
JNK activation potentiates the activation of c-Jun/
AP-1 and the downstream apoptotic genes, although
a role for JNK signaling in protection from cell
death cannot be excluded [22].
After the induction of JNK activation, the increase
in p53 protein levels also preceded the DNA frag-
mentation. This increase was achieved without the
increase in p53 mRNA (Fig. 4). One mechanism to
rapidly and e¡ectively regulate p53 in response to
DNA damage is post-translational modi¢cation
[49]. Recent experiments have suggested that this reg-
ulation is brought about largely through DNA dam-
age triggering a series of phosphorylation events on
the p53 polypeptide. The incubation of cell lines ex-
pressing p53 with the phosphatase inhibitor resulted
in an increase in p53 phosphorylation and increased
levels of p53 protein [50]. p53 has been shown to be
phosphorylated in vitro by a number of kinases, in-
cluding JNK [32]. Further, the radiation-induced p53
kinase activities of UV-irradiated cells in vivo were
co-puri¢ed with JNK [33]. These results suggest that
the accumulation of p53 protein in the cisplatin-
treated rat liver might be due to stabilization through
the phosphorylation by JNK. The rise of p53 protein
levels at 1 h after PH with cisplatin was followed by
the upregulation of p21 mRNA and protein (Figs. 3
and 4). The increase in p21 mRNA was detected at
1 h and accompanied by the appearance of p21 pro-
tein at 2 h after PH. In quercetin-induced apoptosis
in regenerating liver, the upregulation of p21 mRNA
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and protein was also observed [40]. Although the
role of p21 in apoptosis remains somewhat contro-
versial [28], there also is evidence that overexpression
of p21 induced apoptosis [40,51^54]. In regenerating
liver, p21 overexpression seems to be a key factor in
apoptosis. We postulate that the JNK-p53-p21 path-
way is involved in cisplatin-induced apoptosis. Fur-
ther studies are needed, however, to clarify the rela-
tionships between TNF-K, JNK signaling and the
p53 pathway in cisplatin-induced apoptosis.
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